Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126575 · ClinicalTrials.gov registry record · Phase 1
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
A Phase 1 study, sponsored by Stemline Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06126575 is a Phase 1 study that has completed, run by Stemline Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT06126575, a Phase 1 study, has completed, sponsored by Stemline Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral dose of Elacestrant.
Interventions
- DRUG Elacestrant dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06126575
The ClinicalTrials.gov registry entry for NCT06126575 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elacestrant dihydrochloride is the first listed.
NCT06126575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06126575 about?
NCT06126575 is a clinical study titled "A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function". This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral dose of Elacestrant.
What is the current status of trial NCT06126575?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-03-13. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT06126575?
The interventions under investigation include: Elacestrant dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT06126575?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.